BRISTOL-MYERS SQUIBB COMPANY Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment of $25.00 million for the 3-month period ending 2009-06-30, per its 10-K filed 2012-02-17.
Discontinued › Income Statement › Other Income
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments · last filed 2012-02-17
- BRISTOL-MYERS SQUIBB COMPANY defined benefit plan, net periodic benefit cost (credit), gain (loss) due to curtailment for the quarter ending 2009-06-30 was $25.00M.
| Period end | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 3 month |
|---|---|
| 2009-06-30 | $25.00M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |